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ABSTRACT
In this study, an HPLC method with ultraviolet (UV) detection was developed and validated for determination of pazopanib
(PAZ), a multi-targeted tyrosine kinase (TK) inhibitor in bulk drug, tablets formulation, and in human plasma. Oxamniquine
(OXA) was used as internal standard (IS). The analytical column used for the separation was Nucleosil CN with dimensions (i.d.
250 × 4.6 mm and particle size 5 µm). The separation was carried out in isocratic mode with mobile phase constituting
acetonitrile:100 mM sodium acetate buffer (pH 4.5); 40:60, v/v. The developed method was linear in the concentration range of
2–12 µg mL–1 and had a correlation coefficient (r = 0.9998, n = 6). The limits of detection and quantitation (LOD and LOQ) were
0.27 and 0.82 µg mL–1, respectively. The relative standard deviations for the inter- and intra-assay precisions were below 3.61 %
and the accuracy of the method was 96.69–104.15 %. The degradation products were resolved from the intact drug, proving the
stability-indicating property of the proposed method. The recovery values were 100.17–103.98 % (± 1.81–4.02) for determination
of PAZ in human plasma. The results indicated the versatility of the new method in estimation of PAZ during pharmaceutical
quality control (QC) and therapeutic drug monitoring (TDM).
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1. Introduction
An important role of vascular endothelial growth factor receptor
(VEGF) in quite a few tumor forms has been reported.1–3 The
dysregulation of platelet derived growth factor (PDGF)4 and
epidermal growth factor (EGF)5 also play an important role in
propagation of tumor cell. Pazopanib (PAZ; GW-786034) chemi-
cally known as 5-({4-[(2,3-Dimethyl-2H-indazol-6-yl) (methyl)
amino]-2-pyrimidinyl}amino)-2-methylbenzene-sulfonamide
(Fig. 1) is tyrosine kinase inhibitor (multi-targeted and orally
active). The targets for PAZ are VEGFR-1, -2, and -3, PDGFR-a,
PDGFR-b, c-Kit and act by inhibiting auto-phosphorylation of
growth factor receptor (intracellular TK domain). PAZ competes
with ATP to bind to the intracellular TK domain thus, blocking
downstream signal transduction.6 The recommended dose of
PAZ is not more than 800 mg once daily for treatment of soft tis-
sue sarcoma or renal cell carcinoma. Pharmacokinetic studies
have revealed peak plasma concentration of 58.1 µg mL–1 and
mean AUC of 1037 µg h mL–1 for PAZ after a dose of 50–2000 mg.
The absorption of PAZ in cancer patients is slow and the
bioavailability of 800 mg tablet in these patients is 21 %. The PAZ
accumulates after continuous once daily dosing for 22 days and
the drug is present in the systemic circulation as intact PAZ and
not as metabolites of PAZ. PAZ is 99 % plasma protein bound
and is eliminated mainly through feces and around 4 % through
renal route.7
Environmental conditions (e.g. temperature, humidity, etc.)
that vary during manufacturing, transportation, distribution
and storage of drugs have great effect on their potency and
therefore the quality of the pharmaceutical product (Votrient®
tablets; Novartis, USA). As well, impurities and/or degradation
products present in the drug substance can alter the pharmaco-
logical behavior of the active pharmaceutical ingredient.4–7
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Figure 1 Chemical structure of pazopanib (PAZ) and oxamniquine (OXA).
ISSN 0379-4350 Online / ©2017 South African Chemical Institute / http://saci.co.za/journal
DOI: http://dx.doi.org/10.17159/0379-4350/2017/v70a9
Several adverse effects like eye disorders (e.g. retinal detach-
ment/tear) and gastrointestinal disorders (e.g. pancreatitis)7
have been reported with votrient® tablets during the post-
marketing surveillance. These adverse effects can also be attrib-
uted to the degradation products of PAZ; therefore, necessitat-
ing stability testing of the active PAZ substance. Saudi Arabian
weather conditions are highly variable and thus could affect the
quality of PAZ. PAZ tablets are imported from outside Saudi
Arabia and therefore may be exposed to great climatic variation
from manufacturing to national distribution. The stability test-
ing can used to optimize for the appropriate packing process,
determining storage conditions, shelf life and expiry date.8–13
These reasons warrant the need of method for assessing the
quality control (QC) of PAZ-containing tablets.
An exposure–response relationship has been observed during
therapy with PAZ.7 Therefore, therapeutic drug monitoring
(TDM) of PAZ could be a valuable tool in clinical practice. For
pharmaceutical QC of PAZ and its TDM, a validated reliable
analytical method is necessary. The reported methods for deter-
mination of PAZ are limited14–18 and mostly suffer from major
drawbacks such as: (1) their applications are limited to the bulk
drug and/or dosage forms,14–16 but not applicable to plasma
samples; (2) the method devoted to analysis of plasma samples is
relying on intensive and costly instrumental techniques such as
liquid chromatography-tandem mass spectrometry;18 which is
not available in most QC and/or clinical laboratories. In this
study, an HPLC method based on UV detection was developed
and validated for stability testing of PAZ and its therapeutic drug
monitoring. The developed method was selective and sensitive
and it fulfilled the requirements of the International Conference




Pazopanib (PAZ) standard drug was provided as gift sample
by Saudi Food & Drug Authority Laboratories (Riyadh, Saudi
Arabia). Oxamniquine (OXA) was purchased from Sigma-Aldrich
Corporation (Saint Louis, CA, USA). Votrient® film-coated tablets
(GlaxoSmithKline, Philadelphia, PA, USA) obtained from local
market contained 200 mg of PAZ per tablet as per the label claim.
King Khalid University Hospital (Riyadh, Saudi Arabia)
provided the human plasma and the plasma was stored at –20 °C
till analysis. HPLC grade solvents obtained from (Merck,
Darmstadt, Germany) were used for analysis. Millipore Milli-Q®
UF Plus apparatus (Millipore, Molsheim, France) was used to
obtain ultra-pure water for the analysis.
2.2. Chromatographic System and Conditions
HPLC system from Shimadzu controlled by ‘LC solution’ soft-
ware (Shimadzu Corporation, Kyoto, Japan) equipped with
pump LC-20AD VP, auto-sampler SIL-20A, co-sense BA LC
system, column oven CTO-20A, UV–VIS detector SPD-20A and
system controller CBM-20A. The analytical column used for the
separation was nucleosil CN manufactured by Macherey-Nagel
GmbH (Düren, Germany) with dimensions (i.d. 250 × 4.6 mm
and particle size 5 µm). The analysis was performed under
constant column temperature of 25 ± 2 °C. The separation was
carried out in isocratic mode with mobile phase constituting
acetonitrile:100 mM sodium acetate buffer (pH 4.5); 40:60, v/v.
Prior to use the mobile phase was filtered using millipore 0.45 µm
filter and degassed on an ultrasonic bath. After optimization the
ideal flow rate was found to be 1.2 mL min–1 and the PAZ was
detected at 270 nm. Samples of 20 µL were injected into the
HPLC system during the analysis.
2.3. Preparation of PAZ Standard and Sample Solutions
A stock solution of 1 mg mL–1 in methanol was prepared by
accurately weighing (5 mg) of PAZ and dissolving in 5 mL
methanol. Working standard of 200 mg mL–1 was obtained by
diluting the stock solution with methanol. The tablet samples
(Votrient®) were prepared by weighing 10 tablets, calculating
their average weight and then crushing them to fine powder.
25 mg equivalent powder of PAZ was diluted with methanol to
obtain a solution of 1 mg mL–1. The resulting solution was filtered
through 0.45 µm membrane filter. The stock solution was diluted
to obtain concentration ranging from 2–12 µg mL–1 (2, 4, 6, 8, 10,
12 µg mL–1) and were subjected to analysis by the proposed
method.
2.4. Preparation of OXA Internal Standard Solution
Stock solution of OXA 1 mg mL–1 in methanol was prepared by
dissolving 25 mg of OXA in 25 mL of methanol. The working
solution of OXA 200 µg mL–1 was prepared from the stock solu-
tion.
2.5. Forced Degradation
2.5.1. Acid and Alkali Hydrolysis
A 500 µL aliquot of PAZ working standard (200 µg mL–1l) were
pipetted into 10 mL volumetric flasks (n = 10) and were added
with 8.5 mL water. The flasks were separated into two groups of
five each and were added with either 1 mL of 10 N hydrochloric
acid or 10 N sodium hydroxide. The resulting solutions were
initially heated for 5 min on hot plate and then transferred to a
water bath (70 °C). The samples were removed from the water
bath after 1 h and allowed to cool down to room temperature
(25 ± 2 °C). The samples were then neutralized either with acid
or base (equivalent amount) and 20 µL of these neutralized
samples were injected into the HPLC system.
2.5.2. Oxidation
A 500 µL aliquot of PAZ working standard (200 µg mL–1) were
pipetted into 10 mL volumetric flasks (n = 5) and were added
with 7.5 mL water. These flasks were added with 2 mL of 30 %
hydrogen peroxide solution. The samples flasks were placed
inside a water bath (70 °C). The samples were withdrawn from
the flasks in water bath at intervals of 15, 30, 60, 120, 180, 240, and
300 min. After withdrawing the samples were allowed to cool to
the room temperature (25 ± 2 °C) and then 20 µL were injected in
to the HPLC system.
2.6. Construction of Calibration Curve for Analysis of
Plasma Samples
Blank human plasma was spiked with varying PAZ and OXA
(internal standard) fixed concentration of 10 µg mL–1 to prepare
the calibration standards in the range 2–12 µg mL–1. Aliquots of
500 µL of spiked plasma were added to 500 µL of methanol,
vortexed for 30 s and then centrifuged at 13 000 rpm for 20 min.
The supernatant was pipetted out and filtered through 0.2 µm
millipore syringe filters. A 20 µL aliquot of the filtered sample
was injected into the HPLC system for analysis. The calibration
curve contained six calibration points and the calibration plot
was constructed as peak area ratio of PAZ to OXA (y-axis) versus
PAZ concentration (x-axis). Each calibration standard was ana-
lyzed three times and the slope, intercept and correlation
coefficient (r) calculated.
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3. Results and Discussion
3.1. Method Development and Chromatographic Condition
Optimization
HPLC is widely used in quality control, pharmaceutical analysis
and clinical settings as it provides acceptable sensitivity, more
convenient and cheaper. PAZ contains a chromophore center
(Fig. 1) and therefore, a method based on UV detection was
developed and validated for estimation of PAZ in bulk and
dosage form for QC analysis. The developed method was also
validated for estimation of PAZ in plasma for TDM, pharma-
cokinetic and toxicokinetic analysis. The OXA (Fig. 1) was
selected as internal standard on the basis that it also shows maxi-
mum absorption in the same region as PAZ (270 nm) (Fig. 2). It
was also determined by the preliminary experiments that the
peaks (PAZ and OXA) are resolved (Fig. 3B).
The chromatographic conditions were optimized and included
the selection of mobile phase and column. Several mobile phases
systems and columns were studied during the analysis and the
most appropriate mobile phase was found to be aceto-
nitrile:100 mM sodium acetate buffer (40:60, v/v), adjusted to pH
4.5 with 100 % acetic acid. The nucleosil CN with dimensions
(i.d. 250 × 4.6 mm and particle size 5 µm) manufactured by
Macherey-Nagel GmbH (Düren, Germany) analytical column
provided the most acceptable separation. The optimum flow
rate for the mobile phase was found to be 1.2 mL mL–1 an isocratic
mode. The column temperature (25 ± 2 °C) during the analysis
was not varied during analysis. The total run time under these
optimized conditions was 7 min and the retention time for PAZ
was found to be 5.55 ± 0.04 and that for the OXA was found to
be 3.70 ± 0.02 min (n = 5) (Fig. 3). The tabular format for the
chromatographic conditions is presented in Table 1.
3.2. Method Validation
3.2.1. Linearity and Sensitivity
Three different calibration curves were generated independently
and with the 6-concentration standards 2, 4, 6, 8, 10, 12 µg mL–1
and each standard was run thrice during each run. The
least-square method was used for the regression analysis and
the standard deviation of each calibration standard (triplicate)
was less than 2 %. The generated equation for the calibration
curve was: Y = –0.042 + 0.1746 C (r = 0.9998). Y represents the
relative detector signal, C represents the concentration of PAZ
and the correlation coefficient is represented by r. Signal-to-
noise ratio19 was used for determination of limit of detection
(LOD) and limit of quantitation (LOQ). The LOD and LOQ
values were 0.27 and 0.82 µg mL–1, respectively.
3.2.2. Precision and Accuracy
ICH guidelines were followed to measure the precision of the
developed method. Five injections of the six calibration standard
(2, 4, 6, 8, 10 and 12 µg mL–1) were run repeatedly to determine
the intra-assay precision. The relative standard deviation (RSD)
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Figure 2 Absorption spectra of pazopanib (PAZ) and oxamniquine
(OXA) against methanol. Concentrations of both PAZ and OXA were
10 µg mL–1 in methanol.
Table 1 Chromatographic parameters for PAZ and OXA by the proposed
HPLC method.
Parameter Value
Retention time of PAZ 5.55 ± 0.04
Retention time of OXA (IS) 3.70 ± 0.02
Capacity factor 2.67
Resolution 2.80
Peak asymmetry at 10 % peak height 1.36
Number of theoretical plates 3657
Height equivalent to theoretical plate /µm 273
Correlation coefficient /r 0.9998
Slope (b)  ± SD 0.1746
Intercept (a)  ± SD –0.042
LOD /µg mL–1 0.27
LOQ /µg mL–1 0.82
Linear range /µg mL–1 2–12
Figure 3 Representative chromatogram of 10 µg mL–1 of standard solu-
tion of the internal standard, OXA (A) and a mixture solution containing
10 µg mL–1 of both standard PAZ and OXA (B).
calculated for the intra-assay precision did not exceed 3.61 %
(Table 2). Inter- assay precision for PAZ at concentration levels of
(2, 4, 6, 8, 10 and 12 µg mL–1) was determined by repeating the
analysis of the same concentration thrice in three different runs.
The RSD values of inter-assay precision did not exceed 0.14 %,
proving the satisfactory precision of the method.19
Accuracy of the method was determined by spiking known
concentrations of PAZ (2, 4, 6, 8, 10 and 12 µg mL–1) to placebo
matrix for tablets. Five replicates for each concentration were
injected and the concentrations were back calculated from the
calibration curve. The concentrations recovered are presented as
percentage of the nominal concentration and were in the range
96.69–104.15 % (Table 3). The developed method showed
acceptable accuracy.19
3.2.3. Robustness and Ruggedness
The ruggedness of the method was evaluated by altering the
most important optimized chromatographic parameters within
the range 1–10 % and not interfering with other parameters. The
parameters that were studied for the robustness included
mobile phase composition, flow rate of mobile phase, change in
pH, and column temperature. The results obtained indicated the
robustness of the method and minute changes within 10 % did
not significantly alter the PAZ estimation.
The method for PAZ was tested for its robustness using mobile
phase from different manufacturers and the retention time did
not change significantly with the mobile phases from different
manufacturers. The relative standard deviation recorded was
0.29–1.85 % inferring the methods ruggedness.
3.2.4. Sample Solution Stability
In order to check the bench top stability of the drug during
experimentation, the drug solution (8 µg mL–1) was kept was
subjected to analysis at 24, 48 and 72 h under normal laboratory
conditions (25 ± 2 °C). The drug was also tested under refriger-
ated condition (8 ± 1 °C) after 72 h of storage. No significant
change in the samples was found over the tested period indicat-
ing stability of the drug solution and the RSD for the samples
stored at (8 ± 1 °C) and (25 ± 2 °C) was found to be 1.27 % and
1.04 %, respectively.
3.2.5. System Suitability
The instrument was checked for system suitability prior to
sample analysis. The parameters analyzed included retention
factor (K), repeated injections effect (similar to precision analysis),
number of theoretical plates, tailing factor (T) and peak resolu-
tion (Rs) for PAZ and OXA. Using a 10 µg mL–1 for PAZ the capac-
ity factor was found to be 2.67 inferring that the PAZ peak is
resolved efficiently from the void volume. A RSD of 0.25 %, indi-
cated excellent injection repeatability. Peak symmetry of 1.36
indicated good peak symmetry. The PAZ and OXA were
resolved properly indicated by the peak resolution of 2.80. The
number of theoretical plates using Nucleosil CN with dimensions
(i.d. 250 × 4.6 mm and particle size 5 µm) was found to be 3657
establishing adequate column efficacy. The results obtained
from the analysis by the proposed HPLC method indicate the
efficiency of the method for the routine analysis PAZ.
3.3. Stability-indicating Study
The ICH guidelines20 recommends stress testing of drug
substance to interpret the intrinsic stability of the API as the drug
substance can pass through stressful situations during the
manufacturing. Hydrolytic and oxidation tests are recom-
mended by the ICH guidelines for stress testing. A method that
can quantify drug as well as resolve its degradation products is
identified as best stability-indicating method. PAZ was stress
tested as described in the experimental section (acid hydrolysis,
alkali hydrolysis and oxidation. Chromatograms from acid and
alkali hydrolysis of PAZ indicate that no degradation of PAZ
occurred under these conditions when matched with chromato-
grams of blank solutions (Figs. 4–5). However, post-oxidation
hydrolysis degradation products could be seen in the chromato-
gram (Fig. 6). As is clear from the chromatogram that the degra-
dation products could be separated completely from PAZ using
the proposed method, establishing stability-indicating property
of the proposed method. The kinetics of PAZ degradation in
oxidative conditions was studied. Plot of time versus both peak
areas of PAZ and their corresponding ln values is shown in Fig. 7.
Straight line with good correlation coefficient (0.9986) was
obtained from linear regression analysis of time-log peak area
plot (Fig. 7). This confirmed that the oxidative degradation of
PAZ behaved as first-order reaction.21 The reaction rate constant
(K) was calculated from the slope of the regression equation
(Fig. 7); K = – slope × 2.303.21 The K value was calculated and
found to be 6 ×10–2 min–1 with t½ value of 11.15 min.
3.4. Selectivity of the Method
PAZ and OXA were well separated under the optimized chro-
matographic conditions and the representative chromatograms
are given in Fig. 3. The chromatogram obtained from analysis of
Votrient® tablet solution spiked with OXA was identical to that of
the standard solution indicating that the tablet excipients had no
interference with the analysis. Thus, indicating selectivity of the
method for quality control analysis of PAZ.
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Table 2 Precision and accuracy data for analysis of PAZ by the proposed
HPLC method.
Nominal Measured Recovery RSD
concentration concentration
/µg mL–1 /µg mL–1 /% /%
Within run
2 2.08 104.15 1.59
4 4.04 101.02 0.51
6 5.89 98.09 0.27
8 7.90 98.79 0.54
10 9.96 99.61 1.87
12 12.13 101.09 3.61
Between runs
2 2.00 99.78 0.11
4 3.88 96.97 0.14
6 5.80 96.69 0.09
8 7.75 96.85 0.12
10 9.78 97.82 0.10
12 11.90 99.14 0.07
Table 3 Application of the proposed HPLC method in the determination
of PAZ in Votrient® tablets.
Taken concentration Measured concentration Recovery
/µg mL–1 /µg mL–1 /% ± RSD
2 1.93 95.92 ± 0.53
4 3.99 99.87 ± 1.14
6 5.82 97.05 ± 2.21
8 7.86 98.29 ± 0.22
10 9.91 99.15 ± 0.78
12 12.26 102.19 ± 0.49
The developed methods selectivity was also accessed in
plasma. Blank human plasma was used to access the selectivity
and recognize the peaks due to the plasma constituents and
their resolution from the peaks of PAZ and OXA (IS). Figure 8
represents the chromatograms obtained from the blank plasma,
plasma spiked with OXA, and plasma spiked with both PAZ and
OXA. As is evident from the chromatograms that the PAZ and
OXA are completely separated from the endogenous plasma
constituents, thus, indicating selectivity of the method in
plasma.
3.5. Applications of the Method
The method was successfully applied for estimation of PAZ in
Votrient® tablets and human plasma. Varying concentrations of
tablets solutions were taken and subjected to the analysis by the
proposed method. Recovery values were 95.92–102.19 % and the
relative standard deviation (RSD) values were 0.22–2.21 %
(Table 3) indicating the reliability of the method for quality
control of PAZ in bulk and dosage form. As well, human plasma
samples were spiked with varying PAZ concentrations (Table 4)
within its reported therapeutic plasma levels,7,22 and the spiked
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Figure 5 Alkali stress testing of PAZ. Panel A is the blank NaOH solution
solution without PAZ. Panels B and C are PAZ standard solutions that
have been subjected to NaOH hydrolysis for 5 min and 1 h (in a water
bath at 70 °C), respectively.
Figure 4 Acid stress testing of PAZ. Panel A is the blank HCl solution
without PAZ. Panels B and C are PAZ standard solutions that have been
subjected to HCl acid hydrolysis for 5 min and 1 h (in a water bath at
70 °C), respectively.
samples were subjected to the analysis by the proposed method.
The results were satisfactory in terms of the accuracy and preci-
sion as the recovery values were 100.17–103.98 % and RSD
did not exceed 4.02 % (Table 4). These data indicate the applica-
bility of the proposed HPLC method for the accurate determina-
tion of PAZ in plasma in bioequivalence and pharmacokinetic
studies.
4. Conclusion
The present study represents the first report that deals with
the development of an HPLC method with ultraviolet (UV)
detection for determination of PAZ, a multi-targeted tyrosine
kinase inhibitor in bulk drug, tablets formulation, and in human
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Figure 7 Kinetic study for stressed oxidation of PAZ. The time-peak area
curve () and the linear plot of time-log peak area () with its fitting
equation and correlation coefficient.
Figure 8 Representative chromatograms from (A) blank PAZ-free human
plasma, (B) plasma spiked with internal standard, OXA (5 µg mL–1),
(C) plasma spiked with OXA (5 µg mL–1) and PAZ (5 µg mL–1).
Figure 6 Oxidative stress testing of PAZ. Panel A is the chromatogram of
blank hydrogen peroxide solution. Panel B is the chromatogram of a
mixture of PAZ and hydrogen peroxide injected directly after mixing.
Panel C is the chromatogram of a mixture of PAZ and hydrogen peroxide
injected after incubation for 5 h in a water bath at 70 °C.
plasma samples. The stability-indicating property of the method
was documented as per the recommendations of ICH guide-
lines. In addition, the applicability of the method for determina-
tion of PAZ in human plasma samples was proved. From the
economical point of view, the method involved the native
UV-absorbing property of PAZ, rather than relying on expen-
sive instrumentation as LC-MS/MS. Statistical analysis for the
results proved that the method is valid for its routine use in the
pharmaceutical quality control industry and clinical laborato-
ries.
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Table 4 Application of the proposed HPLC method in the determination
of PAZ in spiked human plasma samples.
Spiked concentration Measured concentration Recovery
/µg mL–1 /µg mL–1 /%  ± RSD
4.8 4.99 103.83 ± 1.82
7.2 7.21 100.17 ± 4.02
9.6 9.98 103.98 ± 1.81
12 12.26 101.62 ± 3.97
